ZA201808160B - Bispecific binding proteins and uses thereof - Google Patents

Bispecific binding proteins and uses thereof

Info

Publication number
ZA201808160B
ZA201808160B ZA2018/08160A ZA201808160A ZA201808160B ZA 201808160 B ZA201808160 B ZA 201808160B ZA 2018/08160 A ZA2018/08160 A ZA 2018/08160A ZA 201808160 A ZA201808160 A ZA 201808160A ZA 201808160 B ZA201808160 B ZA 201808160B
Authority
ZA
South Africa
Prior art keywords
binding proteins
bispecific binding
bispecific
proteins
binding
Prior art date
Application number
ZA2018/08160A
Other languages
English (en)
Inventor
Srinath Kasturirangan
Changshou Gao
Godfrey Rainey
Michelle Morrow
Claire Louise Dobson
Stacey Drabic
Darren Schofield
Gianluca Carlesso
Kristen Pollizzi
Yariv Mazor
Michael Oberst
Scott A Hammond
Brian Lobo
Prakash Manikwar
Jonathan Seaman
Simon Dovedi
Ronald Herbst
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of ZA201808160B publication Critical patent/ZA201808160B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2018/08160A 2016-05-06 2018-12-03 Bispecific binding proteins and uses thereof ZA201808160B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332788P 2016-05-06 2016-05-06
PCT/US2017/031356 WO2017193032A2 (en) 2016-05-06 2017-05-05 Bispecific binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
ZA201808160B true ZA201808160B (en) 2021-08-25

Family

ID=60203374

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/08160A ZA201808160B (en) 2016-05-06 2018-12-03 Bispecific binding proteins and uses thereof

Country Status (28)

Country Link
US (5) US10457732B2 (enExample)
EP (2) EP3452089B1 (enExample)
JP (5) JP6952716B2 (enExample)
KR (3) KR20240096787A (enExample)
CN (1) CN109152835B (enExample)
AR (1) AR108377A1 (enExample)
AU (4) AU2017260365B2 (enExample)
CL (1) CL2018003136A1 (enExample)
CO (1) CO2018012415A2 (enExample)
DK (1) DK3452089T3 (enExample)
ES (1) ES3065767T3 (enExample)
FI (1) FI3452089T3 (enExample)
HR (1) HRP20260393T1 (enExample)
IL (3) IL321475A (enExample)
LT (1) LT3452089T (enExample)
MA (1) MA44885B1 (enExample)
MX (2) MX2018013548A (enExample)
MY (1) MY200335A (enExample)
PL (1) PL3452089T3 (enExample)
PT (1) PT3452089T (enExample)
RS (1) RS67897B1 (enExample)
RU (2) RU2022102446A (enExample)
SG (1) SG11201809089QA (enExample)
SI (1) SI3452089T1 (enExample)
SM (1) SMT202600124T1 (enExample)
TW (4) TWI890267B (enExample)
WO (1) WO2017193032A2 (enExample)
ZA (1) ZA201808160B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. PrzeciwciaƂa skierowane przeciwko biaƂku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CN108367069B (zh) 2015-12-14 2022-08-23 ćźè§‚ćŸșć› æœ‰é™ć…Źćž ćŻčäșŽpd-1撌ctla-4ć…·æœ‰ć…ç–«ććș”æ€§çš„ćŒç‰čćŒ‚æ€§ćˆ†ć­ćŠć…¶äœżç”šæ–čæł•
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
CN110914302A (zh) 2017-06-01 2020-03-24 è”›æ‰˜ć§†ć…‹æ–ŻæČ»ç–—ć­Šè‚Ąä»œæœ‰é™ć…Źćž ćŻæŽ»ćŒ–æŠ—pdl1æŠ—äœ“ćŠć…¶äœżç”šæ–čæł•
CA3086098A1 (en) * 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
KR102845020B1 (ko) 2017-12-28 2025-08-12 난징 레전드 ë°”ìŽì˜€í…ŒíŹ 씚였., 엘티디. Pd-l1에 대한 항ìČŽ 및 ëł€ìŽìČŽ
CN118047873A (zh) * 2017-12-29 2024-05-17 ćœ†ç„„ç”ŸæŠ€è‚Ąä»œæœ‰é™ć…Źćž è°ƒèŠ‚ć…ç–«æŁ€æŸ„ç‚č䜜äžș癌症æČ»ç–—çš„ć•ç‰čćŒ‚æ€§è›‹ç™œèŽš
WO2019233413A1 (en) * 2018-06-05 2019-12-12 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Dimer and use thereof
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
JP7497351B2 (ja) * 2018-11-13 2024-06-10 コンパă‚č ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ăƒȘミテッド ăƒ©ă‚€ă‚ąăƒ“ăƒȘティ ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ăƒă‚§ăƒƒă‚Żăƒă‚€ăƒłăƒˆćˆ†ć­ă«ćŻŸă™ă‚‹ć€šé‡ç‰čç•°æ€§ç”ćˆæ€§æ§‹çŻ‰ç‰©ăŠă‚ˆăłăăźäœżç”š
JP2022525275A (ja) * 2019-03-28 2022-05-12 ă‚šăƒŒăƒ“ăƒŒ ă‚čăƒˆă‚„ăƒŒăƒ‡ă‚Łă‚Ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ăƒ˜ăƒ†ăƒ­ć€šé‡äœ“ă‚żăƒłăƒ‘ă‚ŻèłȘćŠăłăăźäœżç”šæł•
EP3947449A4 (en) 2019-04-01 2022-09-07 Immetas Therapeutics, Inc. BISPECIFIC BINDING MOLECULES THAT TARGET THE TUMORS MICROENVIRONMENT AND AN IMMUNE CHECKPOINT PROTEIN
US12703758B2 (en) 2019-06-19 2026-08-11 Changqing Genrix Biopharmaceutical Co., Ltd. Anti-CD3E/BCMA bispecific antibody and use thereof
CN111269315B (zh) 2019-06-19 2022-04-08 挗äșŹæ™șä»çŸŽćšç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž 针ćŻčbcmaçš„ć•ć…‹éš†æŠ—äœ“
JP2022553176A (ja) * 2019-10-17 2022-12-22 江蘇ćș·ćŻ§æ°ç‘žç”Ÿç‰©ćˆ¶è–Źæœ‰é™ć…Źćž ïŒŻïœ˜ïŒ”ïŒïŒïœïœ„ïŒïœŒïŒ‘äșŒé‡ç‰č異性抗䜓
JP7738914B2 (ja) * 2019-12-05 2025-09-16 ă‚ąăƒŒăƒ™ăƒ« ăƒȘミテッド ïŒŽïœ’ïœ‰ïŒĄïœ˜æŠ—äœ“ăźç”„æˆă€ăăźèŁœé€ æ–čæł•ćŠăłäœżç”šæ–čæł•
WO2021185337A1 (zh) * 2020-03-20 2021-09-23 èŁæ˜Œç”Ÿç‰©ćˆ¶èŻ(烟揰)è‚Ąä»œæœ‰é™ć…Źćž 侀种揌ç‰čćŒ‚æ€§èžćˆè›‹ç™œćŠć…¶ćș”甚
JP7014250B2 (ja) 2020-03-27 2022-02-01 フゾテックæ ȘćŒäŒšç€Ÿ ă‚šăƒŹăƒ™ăƒŒă‚żăźăƒ‰ă‚ąèŁ…çœźç”šăźć‹•äœœèš­ćźšèŁ…çœźă€ćŠăłè©Čć‹•äœœèš­ćźšèŁ…çœźă‚’ç”šă„ăŸăƒ‰ă‚ąèŁ…çœźăźé–‹é–‰ć‹•äœœăźèš­ćźšæ–čæł•ă€‚
KR20230042038A (ko) * 2020-07-27 2023-03-27 ë§ˆíŹëĄœì œë‹‰ìŠ€, ìžíŹ. PD-1 x CTLA-4 읎쀑íŠč읎적 분자의 ì‚Źìš© ë°©ëȕ
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
CN114573704B (zh) * 2021-03-10 2022-11-01 挗äșŹæ‹“ç•Œç”Ÿç‰©ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž Pd-1/ctla-4ç»“ćˆè›‹ç™œćŠć…¶ćŒ»èŻç”šé€”
JP2024514590A (ja) * 2021-04-13 2024-04-02 ăƒĄăƒ‡ă‚ŁăƒŸăƒ„ăƒŒăƒłïŒŒă‚šăƒ«ă‚šăƒ«ă‚·ăƒŒ ïŒ°ïœ„ïŒïŒ‘ćŠăłïœ”ïœ‰ïœïŒïŒ“ă‚’æš™çš„ćŒ–ă™ă‚‹äșŒé‡ç‰č異性抗䜓
US20240182600A1 (en) * 2021-04-20 2024-06-06 Amgen Inc. Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly
CN117377692A (zh) 2021-04-23 2024-01-09 è‹ć·žé€»æ™Ÿç”Ÿç‰©ćŒ»èŻæœ‰é™ć…Źćž Tim-3-é¶ć‘æŠ—äœ“ćŠć…¶ç”šé€”
AR125488A1 (es) * 2021-04-30 2023-07-19 Medimmune Llc ProteĂ­nas de uniĂłn biespecĂ­ficas de pd-1 y de tigit, y usos de las mismas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
IL315307A (en) * 2022-03-07 2024-10-01 Medimmune Llc Treatment methods using CTLA-4 and PD-1 bispecific antibodies
KR20240170833A (ko) 2022-04-04 2024-12-04 드렌 바읎였, ìžíŹ. 덱틎-1 및 cd20에 êČ°í•©í•˜ëŠ” 닀쀑íŠč읎성 êČ°í•© 닚백질 및 읎의 ì‚Źìš© ë°©ëȕ
CA3263276A1 (en) * 2022-07-28 2024-02-01 Medimmune, Llc Polytherapy for the treatment of cancer
JP2025524992A (ja) 2022-07-28 2025-08-01 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ăƒŠăƒŒă‚±ăƒŒ ăƒȘミテッド æŠ—äœ“ïŒè–Źç‰©ă‚łăƒłă‚žăƒ„ă‚ČăƒŒăƒˆăšäșŒé‡ç‰čç•°æ€§ăƒă‚§ăƒƒă‚Żăƒă‚€ăƒłăƒˆé˜»ćźłć‰€ăšăźç”„ăżćˆă‚ă›
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
KR20250173543A (ko) * 2023-04-13 2025-12-10 메디럚 엘엘씚 암 ìč˜ëŁŒë„Œ 위한 pd-1/tigit êČ°í•© 닚백질
WO2024236529A1 (en) 2023-05-17 2024-11-21 Astrazeneca Ab Methods and combinations for treating cervical cancer
WO2024241246A1 (en) * 2023-05-23 2024-11-28 Medimmune, Llc PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC AND cHL
AU2024368294A1 (en) 2023-10-24 2026-05-14 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2026094002A1 (en) 2024-11-04 2026-05-07 Astrazeneca Ab Bispecific t-cell engager molecule combinations for use in treatment of claudin18.2 expressing solid tumors

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 スă‚čăƒ»ăƒ“ă‚Łăƒ»ïŒ’ăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ć€‰æ€§æŠ—äœ“ăźă€ăŸăŸăŻć€‰æ€§æŠ—äœ“ă«é–ąă™ă‚‹æ”čè‰Ż
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グăƒȘă‚«ăƒŒăƒˆ ăƒă‚€ă‚Șăƒ†ă‚ŻăƒŽăƒ­ă‚žăƒŒ ケクチェンă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ æŠ—äœ“äŸć­˜æ€§çŽ°èƒžć‚·ćźłæ€§ă‚’æ”čć–„ă™ă‚‹ăŸă‚ăźæŠ—äœ“ăźă‚°ăƒȘă‚łă‚·ăƒ«ćŒ–æ“äœœ
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiƟtirilmiƟ antikorlar ve konjugatlar.
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp æŠ—äœ“è€‡ćˆäœ“
CN101506238B (zh) 2005-06-30 2013-11-06 æŁźæ‰˜ç§‘ć°”ć…Źćž ć…·æœ‰æé«˜æČ»ç–—æŽ»æ€§çš„æ–čæł•ć’Œæˆćˆ†
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomĂŠner
CN105837690A (zh) * 2006-06-12 2016-08-10 æ–°ć…Žäș§ć“ćŒ€ć‘è„żé›…ć›Ÿæœ‰é™ć…Źćž ć…·æœ‰æ•ˆćș”ćŠŸèƒœçš„ć•é“Ÿć€šä»·ç»“ćˆè›‹ç™œ
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米èżȘçŒȘć°Œæœ‰é™ć…Źćž 怚ç‰čćŒ‚æ€§èĄšäœç»“ćˆè›‹ç™œćŠć…¶ćș”甚
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
KR20100107501A (ko) 2008-01-18 2010-10-05 메디럚 엘엘씚 부위 íŠč읎적 접합을 위한 시슀테읞 ìĄ°ìž‘ 항ìČŽ
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
KR20130056870A (ko) 2010-04-13 2013-05-30 메디럚 엘엘씚 í”ŒëžŒëĄœë„„í‹Ž â…Č형 도메읞에 Ʞ쎈한 닀량ìČŽ 슀ìșíŽë“œ
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
CA2833636A1 (en) * 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN103906533A (zh) 2011-11-07 2014-07-02 米èżȘçŒȘć°Œæœ‰é™ć…Źćž 怚ç‰čćŒ‚æ€§ć’Œć€šä»·ç»“ćˆè›‹ç™œćŠć…¶ç”šé€”
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące biaƂko fuzyjne i sposoby jego otrzymywania
TWI682941B (zh) * 2013-02-01 2020-01-21 çŸŽć•†ć†ç”Ÿć…ƒé†«è—„ć…Źćž ć«ć”Œćˆæ†ćźšć€äč‹æŠ—é«”
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP2832671B1 (en) * 2013-07-30 2016-07-13 Hewlett-Packard Industrial Printing Ltd. Printing apparatus and methods
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
CN103721255A (zh) * 2014-01-07 2014-04-16 è‹ć·žć€§ć­Š ć…±ćŒé˜»æ–­pd-1撌tim-3äżĄć·é€šè·ŻćœšæŠ—èƒƒç™ŒæȻ疗䞭的甚途
WO2015112534A2 (en) * 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
UA122479C2 (uk) * 2014-01-24 2020-11-25 Đ”Đ°ĐœĐ°-ЀарбДр ĐšĐ”ĐœŃĐ”Ń€ Đ†ĐœŃŃ‚Ń–Ń‚ŃŒŃŽŃ‚, Đ†ĐœĐș. Đ’ĐžĐŽŃ–Đ»Đ”ĐœĐ° ĐŒĐŸĐ»Đ”Đșула Đ°ĐœŃ‚ĐžŃ‚Ń–Đ»Đ°, яĐșĐ° Đ·ĐČâ€™ŃĐ·ŃƒŃ”Ń‚ŃŒŃŃ Đ· Đ»ŃŽĐŽŃŃŒĐșĐžĐŒ білĐșĐŸĐŒ ĐżŃ€ĐŸĐłŃ€Đ°ĐŒĐŸĐČĐ°ĐœĐŸŃ— ŃĐŒĐ”Ń€Ń‚Ń–-1 (pd-1)
PL3099717T3 (pl) * 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciaƂa dla TIM-3 i ich zastosowanie
CN104974253A (zh) * 2014-04-01 2015-10-14 äžŠæ”·äž­äżĄć›œć„èŻäžšè‚Ąä»œæœ‰é™ć…Źćž 抗ctla-4/pd-1揌ç‰čćŒ‚æ€§æŠ—äœ“ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćș”甚
CA2949327A1 (en) * 2014-05-29 2015-12-03 Medimmune Limited Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
AU2015271100B2 (en) 2014-06-06 2020-07-30 Redwood Bioscience, Inc. Anti-HER2 antibody-maytansine conjugates and methods of use thereof
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TW201619200A (zh) 2014-10-10 2016-06-01 éș„èżȘ玐有限èČŹä»»ć…Źćž äșșéĄžćŒ–æŠ—ïŒïœïœ˜ïŒ”ïŒæŠ—é«”ćŠć…¶ç”šé€”
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN104987421A (zh) * 2015-05-13 2015-10-21 挗äșŹæŻ”æŽ‹ç”Ÿç‰©æŠ€æœŻæœ‰é™ć…Źćž 抗ctla-4撌pd-1çš„ćŒé‡ćŻć˜ç»“æž„ćŸŸć…ç–«çƒè›‹ç™œ
CN108367069B (zh) * 2015-12-14 2022-08-23 ćźè§‚ćŸșć› æœ‰é™ć…Źćž ćŻčäșŽpd-1撌ctla-4ć…·æœ‰ć…ç–«ććș”æ€§çš„ćŒç‰čćŒ‚æ€§ćˆ†ć­ćŠć…¶äœżç”šæ–čæł•
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses

Also Published As

Publication number Publication date
AU2020204497A1 (en) 2020-07-23
JP7171867B2 (ja) 2022-11-15
CN109152835B (zh) 2022-12-20
US20180022807A1 (en) 2018-01-25
CL2018003136A1 (es) 2018-12-28
JP2024045241A (ja) 2024-04-02
US10457732B2 (en) 2019-10-29
WO2017193032A9 (en) 2018-02-22
RU2766199C2 (ru) 2022-02-09
IL262437A (en) 2018-12-31
JP7898564B2 (ja) 2026-07-31
EP4736954A2 (en) 2026-05-06
TW201741334A (zh) 2017-12-01
US20250074986A1 (en) 2025-03-06
JP2025090743A (ja) 2025-06-17
KR20190003963A (ko) 2019-01-10
MY200335A (en) 2023-12-20
PL3452089T3 (pl) 2026-05-18
DK3452089T3 (da) 2026-03-16
RU2018142544A3 (enExample) 2021-02-09
IL262437B2 (en) 2023-04-01
IL298286A (en) 2023-01-01
TW202222837A (zh) 2022-06-16
IL262437B (en) 2022-12-01
EP3452089B1 (en) 2025-12-24
JP7651022B2 (ja) 2025-03-25
US11279759B2 (en) 2022-03-22
TWI757290B (zh) 2022-03-11
JP2019520797A (ja) 2019-07-25
MX2018013548A (es) 2019-05-20
MX2022015901A (es) 2023-01-24
SG11201809089QA (en) 2018-11-29
TW202613176A (zh) 2026-04-01
MA44885B1 (fr) 2026-02-27
USRE49908E1 (en) 2024-04-09
KR102490183B1 (ko) 2023-01-20
RU2018142544A (ru) 2020-06-08
IL321475A (en) 2025-08-01
NZ748976A (en) 2025-12-19
ES3065767T3 (en) 2026-05-07
CN109152835A (zh) 2019-01-04
JP6952716B2 (ja) 2021-10-20
TWI831124B (zh) 2024-02-01
AU2023208166A1 (en) 2023-10-12
NZ787944A (en) 2025-12-19
CA3021995A1 (en) 2017-11-09
EP4736954A3 (en) 2026-07-15
AU2017260365B2 (en) 2020-06-25
IL298286B2 (en) 2025-11-01
BR112018072485A2 (pt) 2019-02-19
KR20230013284A (ko) 2023-01-26
MA44885A (fr) 2019-03-13
JP2023012528A (ja) 2023-01-25
CO2018012415A2 (es) 2018-11-30
US20220251204A1 (en) 2022-08-11
KR102674279B1 (ko) 2024-06-12
SMT202600124T1 (it) 2026-05-12
TWI890267B (zh) 2025-07-11
PT3452089T (pt) 2026-03-24
RS67897B1 (sr) 2026-04-30
AU2026204957A1 (en) 2026-07-16
WO2017193032A2 (en) 2017-11-09
IL298286B1 (en) 2025-07-01
US20200172622A1 (en) 2020-06-04
NZ787945A (en) 2025-12-19
FI3452089T3 (fi) 2026-03-17
AR108377A1 (es) 2018-08-15
SI3452089T1 (sl) 2026-05-29
AU2023208166B2 (en) 2026-04-09
AU2017260365A1 (en) 2018-12-20
AU2020204497B2 (en) 2023-04-27
HRP20260393T1 (hr) 2026-05-08
WO2017193032A3 (en) 2017-12-14
KR20240096787A (ko) 2024-06-26
EP3452089A2 (en) 2019-03-13
EP3452089A4 (en) 2020-01-01
LT3452089T (lt) 2026-04-10
RU2022102446A (ru) 2022-03-10
JP2022008601A (ja) 2022-01-13
TW202417514A (zh) 2024-05-01

Similar Documents

Publication Publication Date Title
ES3065767T3 (en) Bispecific binding proteins and uses thereof
IL283115A (en) Proteins that bind CD33 and CD3 bispecifically
ZA202003133B (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
IL258284A (en) Anti-Lag 3 antibodies and their uses
IL257263A (en) Antibodies against angptl8 and their use
IL254517B (en) Antibodies against muc16 and their uses
IL254955A0 (en) Anti-pacap antibodies and their uses
IL287291A (en) A protein that binds to rgma and its use
IL259519B (en) cd131 binding proteins and their uses
PL3292154T3 (pl) PrzeciwciaƂa przeciwko ludzkiemu HER3 i ich zastosowania
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
ZA201901862B (en) Modified factor h binding protein
GB201615588D0 (en) TSLP Binding Proteins
GB201617935D0 (en) Binding compound and uses thereof
GB201614627D0 (en) Antigen binding proteins
GB201617925D0 (en) Proteins and uses
AU2015904924A0 (en) Cd131 binding proteins and uses thereof